Knockout the NK-1R gene or pretreatment with NK-1R antagonists could reduce the degree of cerebral ischemia reperfusion injury (Kalogeris et al., 2016), colitis (Corrigan, Vink & Turner, 2016), arthritis (Chang et al., 2013), pancreatitis (Pintér et al., 2014), respiratory tract inflammation (Martinez & Philipp, 2016), Concanavalin A-induced immune syndrome hepatitis (Thornton & Vink, 2015) and many other neurogenic inflammations reaction (Sirianni et al., 2015). The gene discussed is TACR1; the disease is pancreatitis.